Indokem reported a significant improvement in its consolidated financial results for the quarter ended June 30, 2026 (Q1FY27), with net profit rising 53% year-on-year to ₹10.7 crore. The Mumbai-based chemical manufacturer posted total income from operations of ₹469.2 crore, up from ₹417.4 crore in the corresponding period of the previous year, reflecting robust top-line growth alongside improved operational efficiency.

The Board of Directors approved the unaudited consolidated financial results in a meeting held on July 31, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subsequently published in Business Standard and Mumbai Lakshdeep on August 1, 2026. Indokem’s statutory auditor reviewed the quarterly figures before board approval.

Financial Performance Highlights

Indokem’s consolidated net profit for Q1FY27 stood at ₹10.7 crore, compared to ₹7.0 crore in Q1FY26. Profit before tax increased to ₹10.8 crore from ₹7.0 crore in the year-ago quarter. The company’s earnings per share (EPS) rose to ₹0.38 per share, up from ₹0.25 per share in Q1FY26.

Revenue from operations grew by approximately 12.4% to ₹469.2 crore. This top-line expansion was supported by higher volumes and stable pricing in key chemical segments. The company’s standalone revenue also saw growth, reaching ₹427.3 crore against ₹364.6 crore in the prior year quarter.

Margin Expansion and Operational Efficiency

A key driver of the improved profitability was the expansion in operating margins. While specific EBITDA figures were not explicitly broken out in the extract, the widening gap between revenue and pre-tax profit indicates enhanced cost management. In Q1FY26, profit before tax was ₹7.0 crore on revenue of ₹417.4 crore, implying a pre-tax margin of roughly 1.68%. In Q1FY27, this margin expanded to approximately 2.30% (₹10.8 crore on ₹469.2 crore revenue).

The following table summarises Indokem’s key consolidated financial metrics for Q1FY27:

Standalone Results

On a standalone basis, Indokem reported a net profit of ₹8.6 crore for Q1FY27, compared to ₹3.3 crore in Q1FY26. Standalone revenue from operations was ₹427.3 crore, up from ₹364.6 crore. The standalone profit before tax also rose to ₹8.6 crore from ₹3.3 crore, highlighting strong performance across both consolidated and standalone entities.

What the Numbers Show

The nearly 53% jump in net profit outpaces the 12.4% revenue growth, signalling operational leverage. The expansion in pre-tax margins from ~1.68% to ~2.30% suggests that Indokem is effectively managing input costs or benefiting from a more favourable product mix. With paid-up equity capital remaining stable at ₹278.9 crore, the improved earnings translate directly into higher returns for shareholders, as evidenced by the 52% rise in EPS. Investors should monitor whether this margin expansion is sustainable in subsequent quarters given the volatile nature of chemical raw material prices.

Indokem Limited has closed its trading window for designated persons and their immediate relatives effective July 1, 2026, to prevent potential insider trading ahead of its quarterly financial announcement. The restriction will remain in force until 48 hours after the company declares its unaudited financial results for the quarter ended June 30, 2026. This measure is enforced in accordance with the company's Internal Code of Conduct and the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The company stated that the specific date for the Board Meeting to consider and approve these financial results will be communicated later. To ensure compliance, the Permanent Account Number (PAN) of all designated persons will be frozen by the Central Depository Services (India) Limited, acting as the designated depository. This freeze effectively blocks these individuals from trading in the company's securities during the closure period.

The disclosure was submitted to BSE Limited, where Indokem is listed with the scrip code 504092. Rajesh D. Pisal, the Company Secretary and Compliance Officer, signed the intimation on June 22, 2026, confirming the implementation of these regulatory restrictions.